The druggable genome
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
An assessment of the number of molecular targets that represent an opportunity for therapeutic intervention is crucial to the development of post-genomic research strategies within the pharmaceutical industry. Now that we know the size of the human genome, it is interesting to consider just how many molecular targets this opportunity represents. We start from the position that we understand the properties that are required for a good drug, and therefore must be able to understand what makes a good drug target.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The dataset adds high-quality structural models across a broad range of Gene Ontology (GO) terms36,37, including pharmaceutically relevant classes such as enzymes and membrane proteins38 (Fig. 1d).”
From Highly accurate protein structure prediction for the human proteome (2021) · cites this paper as [38]
In the citing paper
“Proteins have several additional advantages as they are most often the direct mediators of biological processes and form the vast majority of currently druggable targets in disease160.”
From Measuring biological age using omics data (2022) · cites this paper as [160]
In the citing paper
“Only around 20% of the human proteome is considered to be druggable with small-molecule antagonists.”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [2]
In the citing paper
“Although this has been a highly effective approach, it has left potential drug targets undrugged or underdrugged45.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [45]
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,760 · cited 1×
“identified 483 targets, and concluded that there could be 5,000–10,000 potential targets on the basis of an estimate of the number of disease-related gene”
BackgroundMetabolite profiling for plant functional genomics
Fiehn, O., Kopka, J., Dörmann, P., Altmann, T., Trethewey, R. N., & Willmitzer, L. (2000) · Nature Biotechnology · doi:10.1038/81137 · Cited by 2,127 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
BackgroundComparative Genomics of the Eukaryotes
Rubin, G. M., Yandell, M. D., Wortman, J. R., Gabor, G. L., Miklos, Nelson, C. R., Hariharan, I. K., Fortini, M. E., Li, P. W., Apweiler, R., et al. (2000) · Science · doi:10.1126/science.287.5461.2204 · Cited by 1,698
Apweiler, R. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.37 · Cited by 1,079
A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations
Raamsdonk, L. M., Teusink, B., Broadhurst, D., Zhang, N., Hayes, A., Walsh, M. C., Berden, J. A., Brindle, K. M., Kell, D. B., Rowland, J. J., et al. (2001) · Nature Biotechnology · doi:10.1038/83496 · Cited by 1,005 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
BackgroundTweeddale, H., Notley-McRobb, L., & Ferenci, T. (1998) · Journal of Bacteriology · doi:10.1128/jb.180.19.5109-5116.1998 · Cited by 393 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
Background
Cited by
Items 601–700 of 1,029
Worth, C. L., Kleinau, G., & Krause, G. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007011 · Cited by 102
“It is estimated that 30–50% of current drug targets are GPCRs [11,12], which is in contrast to the small proportion of genes in the human genome that are predicted to encode GPCRs, illustrating the importance of these proteins both medically and pharmaceutically.”
BackgroundInfluentialHigh-Throughput Screening for the Discovery of Enzyme Inhibitors
Lloyd, M. D. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00523 · Cited by 89
Skinner, A. L., & Laurence, J. S. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21378 · Cited by 84
Protein kinase CK2: a newcomer in the ‘druggable kinome’
Pagano, M. A., Cesaro, L., Meggio, F., & Pinna, L. A. (2006) · Biochemical Society Transactions · doi:10.1042/bst0341303 · Cited by 84
GPCR-OKB: the G Protein Coupled Receptor Oligomer Knowledge Base
Khelashvili, G., Dorff, K. C., Shan, J., Camacho‐Artacho, M., Skrabanek, L. A., Vroling, B., Bouvier, M., Devi, L. A., George, S. R., Javitch, J. A., et al. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq264 · Cited by 84
“Since they are the largest family of membrane proteins in mammalian genomes, and are implicated in many biological responses [2], it is not surprising that GPCRs also constitute the largest family of membrane protein targets for therapeutic compounds [3].”
BackgroundProtein NMR in biomedical research
Jahnke, W., & Widmer, H. M. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3382-3 · Cited by 97
Ubiquitin-dependent regulation of G protein-coupled receptor trafficking and signaling
Marchese, A., & Trejo, J. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.11.024 · Cited by 102
Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery
Barnes, M. R., Harland, L., Foord, S. M., Hall, M. D., Dix, I., Thomas, S., Williams-Jones, B. I., & Brouwer, C. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2944 · Cited by 83
“Table 1 illustrates some key areas in which substantial pharmaceutical R&D efforts are ongoing, but in which we think greater progress could be achieved in a pre-competitive and collaborative manne”
BackgroundCell-Free Protein Synthesis Approach to Biosensing hTRβ-Specific Endocrine Disruptors
Salehi, A. S. M., Tang, M. J. S., Smith, M. T., Hunt, J. M., Law, R. A., Wood, D. W., & Bundy, B. C. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.6b04034 · Cited by 85
Druggable genome and precision medicine in cancer: current challenges
Dupont, C., Riegel, K., Pompaiah, M., Juhl, H. H., & Rajalingam, K. (2021) · FEBS Journal · doi:10.1111/febs.15788 · Cited by 86
Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs)
Saraswat, A. L., Vartak, R., Hegazy, R. R., Patel, A., & Patel, K. R. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103387 · Cited by 93
canSAR: an integrated cancer public translational research and drug discovery resource
Halling-Brown, M. D., Bulusu, K. C., Patel, M., Tym, J. E., & Al-Lazikani, B. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr881 · Cited by 84
“As well as providing this useful annotation, it is possible to infer druggability by precedence through the presentation of the sequence similarity to the existing targets of launched therapeutics (39).”
BackgroundZhang, X., Wong, S., & Lightstone, F. C. (2013) · Journal of Computational Chemistry · doi:10.1002/jcc.23214 · Cited by 82
Kinases as Druggable Targets in Trypanosomatid Protozoan Parasites
Merritt, C., Silva, L. E., Tanner, A. L., Stuart, K. D., & Pollastri, M. P. (2014) · Chemical Reviews · doi:10.1021/cr500197d · Cited by 89
Is the Pharmaceutical Industry in a Productivity Crisis?
Cockburn, I. (2006) · Innovation Policy and the Economy · doi:10.1086/ipe.7.25056188 · Cited by 82
Evidence for ligandable sites in structured RNA throughout the Protein Data Bank
Hewitt, W. M., Calabrese, D. R., & Schneekloth, J. S. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.04.010 · Cited by 84
“64 We report here that, consistent with other studies, the transcriptome also likely contains many ligandable sites.”
ResultNgamcherdtrakul, W., & Yantasee, W. (2019) · Translational research · doi:10.1016/j.trsl.2019.08.005 · Cited by 84
“, monoclonal antibodies and small molecule inhibitors) [31], and hence RNA interference with siRNA holds great promise in the field of cancer therapy.”
BackgroundGadolinium theranostics for the diagnosis and treatment of cancer
Robertson, A. G., & Rendina, L. M. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01075h · Cited by 81
Transmembrane helix-helix interactions involved in ErbB receptor signaling
Cymer, F., & Schneider, D. (2010) · Cell Adhesion & Migration · doi:10.4161/cam.4.2.11191 · Cited by 91
“Membrane proteins make up to 30% of all genes in pro- and eukaryotes(2) and about 50% of all currently available drugs target membrane integral proteins, such as cell surface receptors.(3) Enzyme-linked receptors are α-helical membrane proteins that often consist of an extracellular ligand binding domain, a TMD and an…”
BackgroundFrom Laptop to Benchtop to Bedside: Structure-based Drug Design on Protein Targets
Chen, L., K. Morrow, J., T. Tran, H., S. Phatak, S., Du-Cuny, L., & Zhang, S. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799436386 · Cited by 78
“However, in contrast to classic protein inhibitors that target well-defined small molecule’s binding grooves or channels [250, 251], PPIs are usually mediated by flat and large interfaces.”
BackgroundRegulation of immune cell development through soluble inositol-1,3,4,5-tetrakisphosphate
Sauer, K., & Cooke, M. P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2745 · Cited by 81
“Their biochemical properties and available high-throughput assays make ITPKs good potential drug target”
BackgroundJuliano, R. L., Carver, K., Cao, C., & Ming, X. (2013) · Journal of Drug Targeting · doi:10.3109/1061186x.2012.740674 · Cited by 79
“Molecules that act on GPCRs account for approximately 40% of all clinically utilized drugs; further, GPCRs may comprise about 28% of the “druggable genome” and are subject of continuing active drug discovery research (Filmore, 2004; Hopkins & Groom, 2002).”
BackgroundDetermining Appropriate Substrate Conversion for Enzymatic Assays in High-Throughput Screening
Wu, G., Yuan, Y., & Hodge, C. N. (2003) · SLAS DISCOVERY · doi:10.1177/1087057103260050 · Cited by 81
“From equation (1), we know that when [S] >> Km,”
BackgroundMethodInfluentialArmbruster, B. N., & Roth, B. L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.r400030200 · Cited by 80
Implementation of BacMam virus gene delivery technology in a drug discovery setting
Kost, T. A., Condreay, J. P., Ames, R. S., Rees, S., & Romanos, M. A. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.02.017 · Cited by 81
Shigdel, U. K., Lee, S.-J., Sowa, M. E., Bowman, B. R., Robison, K., Zhou, M., Pua, K. H., Stiles, D. T., Blodgett, J. A. V., Udwary, D. W., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006560117 · Cited by 80
Understanding Membrane Protein Drug Targets in Computational Perspective
Gong, J., Chen, Y., Pu, F., Sun, P., He, F., Zhang, L., Li, Y., Ma, Z., & Wang, H. (2018) · Current Drug Targets · doi:10.2174/1389450120666181204164721 · Cited by 87
Machine Learning Informs RNA‐Binding Chemical Space**
Yazdani, K., Jordan, D., Yang, M., Fullenkamp, C. R., Calabrese, D. R., Boer, R. E., Hilimire, T. A., Allen, T. E. H., Khan, R. T., & Schneekloth, J. S. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202211358 · Cited by 91
Torrice, M. M., Bower, K. S., Lester, H. A., & Dougherty, D. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903260106 · Cited by 87
Guo, Z., Li, B., Cheng, L.-T., Zhou, S., McCammon, J. A., & Che, J. (2015) · Journal of Chemical Theory and Computation · doi:10.1021/ct500867u · Cited by 74
What makes a good anti-inflammatory drug target?
Simmons, D. L. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03721-9 · Cited by 90
Cell wall proteome analysis of Mycobacterium smegmatis strain MC2 155
He, Z., & Buck, J. D. (2010) · BMC Microbiology · doi:10.1186/1471-2180-10-121 · Cited by 80
Relation between sequence and structure in membrane proteins
Olivella, M., González, Á., Pardo, L., & Deupí, X. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt249 · Cited by 91
“Because of their relevance to cellular physiology and their accessibility from the extracellular environment, membrane proteins represent a significant portion of therapeutic drug targets (Arinaminpathy et al., 2009; Hopkins and Groom, 2002).”
Inhibition of a viral enzyme by a small-molecule dimer disruptor
Shahian, T., Lee, G. M., Lazic, A., Arnold, L. A., Velusamy, P., Roels, C. M., Guy, R. K., & Craik, C. S. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.192 · Cited by 75
“To assess the dimerization state of KSHV Pr in the presence of DD2, we took two complementary approaches.”
InfluentialTimmons, J. A., Norrbom, J., Schéele, C., Thonberg, H., Wahlestedt, C., & Tesch, P. (2006) · Genomics · doi:10.1016/j.ygeno.2005.09.007 · Cited by 79
“contrast, developing a muscle-specific ‘‘activator’’ of the PGC1a pathway may be extremely challenging, as PGC-1a does not belong to a protein class that is easily amenable to pharmaceutical manipulation by a drug-like molecule [9], and ultimately exercise therapy is probably a simpler option, with greater overall ben…”
BackgroundMartin, É., Polyakov, V. R., Tian, L., & Perez, R. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00166 · Cited by 88
Auld, D. S., Zhang, Y., Southall, N. T., Rai, G., Landsman, M., MacLure, J., Langevin, D., Thomas, C. J., Austin, C. P., & Inglese, J. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8014525 · Cited by 79
Identification of Conserved Proteomic Networks in Neurodegenerative Dementia
Swarup, V., Chang, T. S., Duong, D. M., Dammer, E. B., Dai, J., Lah, J. J., Johnson, E. C. B., Seyfried, N. T., Levey, A. I., & Geschwind, D. H. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107807 · Cited by 78
“Although we showed proteomic modules have less connectivity compared to transcriptomic modules, proteins represent druggable targets (Accelerating Medicines Partnership in Alzheimer’s Disease (AMP-AD), 2019; Griffith et al., 2013; Hopkins and Groom, 2002; Oprea et al., 2018).”
BackgroundResultIdentification of conserved proteomic networks in neurodegenerative dementia
Swarup, V., Chang, T. S., Duong, D. M., Dammer, E. B., Lah, J. J., Johnson, E. E. C. B., Seyfried, N. T., Levey, A. I., & Geschwind, D. H. (2019) · doi:10.1101/825802 · Cited by 78
GIV/Girdin Transmits Signals from Multiple Receptors by Triggering Trimeric G Protein Activation
Garcia‐Marcos, M., Ghosh, P., & Farquhar, M. G. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.613414 · Cited by 78
“In fact, GPCRs represent the target for 30–50% of marketed drugs (3).”
BackgroundIn-Silico Molecular Binding Prediction for Human Drug Targets Using Deep Neural Multi-Task Learning
Lee, K., & Kim, D. (2019) · Genes · doi:10.3390/genes10110906 · Cited by 74
Biochemical applications of mass spectrometry in pharmaceutical drug discovery
Geoghegan, K. F., & Kelly, M. A. (2004) · Mass Spectrometry Reviews · doi:10.1002/mas.20019 · Cited by 92
Dias, D. M. G., & Ciulli, A. (2014) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2014.08.012 · Cited by 89
“pharmacology-second” strategies were established as a dominant trend (Fry, 2006; Hopkins and Groom, 2002; Makley and Gestwicki, 2013; Nú~ nez et al., 2012; Surade and Blundell, 2012; Wells and McClendon, 2007).”
BackgroundMyasein, F., Kim, E., Zhang, J., Wu, H., & El‐Shourbagy, T. A. (2009) · Analytica Chimica Acta · doi:10.1016/j.aca.2009.08.010 · Cited by 77
Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds
Crowther, G. J., Napuli, A. J., Gilligan, J. H., Gagaring, K., Borboa, R., Francek, C., Chen, Z., Dagostino, E., Stockmyer, J. B., Wang, Y., et al. (2010) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2010.08.005 · Cited by 84
“Furthermore, considering that roughly 2 to 5% of an organism’s genes may have legitimate potential as drug targets [61], the number of proteins tested here was relatively small due to the labor-intensive requirement of optimizing a separate biochemical assay for each protein.”
BackgroundIdentification and Characterization of Receptor-Specific Peptides for siRNA Delivery
Ren, Y., Hauert, S., Lo, J. H.-J., & Bhatia, S. N. (2012) · ACS Nano · doi:10.1021/nn301975s · Cited by 82
“R NA interference (RNAi) offers an attractive means to silence gene expression with extraordinary specificity, particularly for the subset of candidate therapeutic gene targets that are considered “undruggable”.(1) This capability is particularly appealing for diseases with complex genotypic alterations such as cancer.”
Prediction of disease–gene–drug relationships following a differential network analysis
Zickenrott, S., Angarica, V. E., Upadhyaya, B. B., & del Sol, A. (2016) · Cell Death & Disease · doi:10.1038/cddis.2015.393 · Cited by 75
“37 In addition, we applied our methodology to three disease-control case studies, for which there is differential gene expression data, to predict disease – gene – drug relationships constituting prospective clinical treatments being subject to future validations.”
BackgroundMethodRalston, K. S., & Hill, K. L. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020101 · Cited by 77
“fraction of proteins considered to be good drug targets [33,34].”
BackgroundTherapeutic targeting of senescent cells in the CNS
Riessland, M., Ximerakis, M., Jarjour, A. A., Zhang, B., & Orr, M. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01033-z · Cited by 77
“Druggability refers to the likelihood that a specific biological target can be effectively modulated by a drug-like molecule 242,243 .”
Roles of G-protein-coupled receptor signaling in cancer biology and gene transcription
Spiegelberg, B. D., & Hamm, H. E. (2006) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.002 · Cited by 76
Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer
Mullenders, J., & Bernards, R. (2009) · Oncogene · doi:10.1038/onc.2009.295 · Cited by 82
Top Down Proteomics of Human Membrane Proteins from Enriched Mitochondrial Fractions
Catherman, A. D., Li, M., Tran, J. C., Durbin, K. R., Compton, P. D., Early, B. P., Thomas, P. M., & Kelleher, N. L. (2013) · Analytical Chemistry · doi:10.1021/ac3031527 · Cited by 76
AlignMe—a membrane protein sequence alignment web server
Stamm, M., Staritzbichler, R., Khafizov, K., & Forrest, L. R. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku291 · Cited by 76
Chen, J., & Zhang, S. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw059 · Cited by 82
Durán, R. C., Wei, H., Kim, D. H., & Wu, J. Q. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12541 · Cited by 81
Proteomics in Drug Development: The Dawn of a New Era?
Frantzi, M., Latosińska, A., & Mischak, H. (2019) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201800087 · Cited by 79
Montero-Melendez, T., Nagano, A., Chelala, C., Filer, A., Buckley, C. D., & Perretti, M. (2020) · Nature Communications · doi:10.1038/s41467-020-14421-x · Cited by 75
Carpenter, T. S., Bond, P. J., Khalid, S., & Sansom, M. S. P. (2008) · Biophysical Journal · doi:10.1529/biophysj.108.131078 · Cited by 84
Parenty, G., Appelbe, S., & Milligan, G. (2008) · Biochemical Journal · doi:10.1042/bj20071689 · Cited by 75
The flagellum of Trypanosoma brucei: New tricks from an old dog
Ralston, K. S., & Hill, K. L. (2008) · International Journal for Parasitology · doi:10.1016/j.ijpara.2008.03.003 · Cited by 89
Synthesis of membrane proteins in eukaryotic cell‐free systems
Sachse, R., Wüstenhagen, D. A., Šamalíková, M., Gerrits, M., Bier, F. F., & Kubick, S. (2012) · Engineering in Life Sciences · doi:10.1002/elsc.201100235 · Cited by 74
“Abbreviations: CFPS, cell free protein synthesis; EGFR, epidermal growth factor receptor; E-PCR, expression polymerase chain reaction; Grb2, growth factor receptor-bound protein 2; EGFRtrunc, EGFR with vIII deletion, endogenenous signal peptide substituted by melittin signal sequence; Mel, melittin signal peptide; PTM…”
MethodBocquet, N., Kohler, J., Hug, M. N., Kusznir, E. A., Rufer, A. C., Dawson, R. J. P., Hennig, M., Ruf, A., Huber, W., & Huber, S. (2015) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2015.02.014 · Cited by 74
“This is an open access article under the largest family of proteins targeted bymarketed small molecules and GPCRs constitute 25% of the all drug-target families of approved medicines [1,2].”
BackgroundLigand-based receptor identification on living cells and tissues using TRICEPS
Frei, A. P., Moest, H., Novy, K., & Wollscheid, B. (2013) · Nature Protocols · doi:10.1038/nprot.2013.072 · Cited by 81
The opsins of the vertebrate retina: insights from structural, biochemical, and evolutionary studies
Nickle, B., & Robinson, P. R. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7253-1 · Cited by 84
Han, L., Zheng, C., Xie, B., Jia, J., Xiao, H., Zhu, F., Lin, H., Chen, X., & Chen, Y. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.02.015 · Cited by 78
Probing Heterotrimeric G Protein Activation: Applications to Biased Ligands
Denis, C., Saulière, A., Galandrin, S., Sénard, J., & Galès, C. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799040466 · Cited by 74
“Accordingly, GPCRs do not function as simple on-off switch but rather as filters capable of selecting activation of specific signals and thus generating textured responses to ligands, a phenomenon often referred to as ligand-biased signaling.”
SAR by NMR: Putting the Pieces Together
Hajduk, P. J. (2006) · Molecular Interventions · doi:10.1124/mi.6.5.8 · Cited by 86
Einstein, R., Jordan, H., Zhou, W., Brenner, M., Moses, E. G., & Liggett, S. B. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801319105 · Cited by 74
“Indeed, it has been estimated that 50% of pharmaceuticals are directed at GPCRs or their immediate downstream signaling events (2, 3).”
BackgroundRational Design of Small Molecules Targeting Oncogenic Noncoding RNAs from Sequence
Disney, M. D., & Angelbello, A. J. (2016) · Accounts of Chemical Research · doi:10.1021/acs.accounts.6b00326 · Cited by 76
Laufer, S., Hauser, D. R. J., Domeyer, D. M., Kinkel, K., & Liedtke, A. J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701529q · Cited by 73
A Treatise to Computational Approaches Towards Prediction of Membrane Protein and Its Subtypes
Butt, A. H., Rasool, N., & Khan, Y. D. (2016) · The Journal of Membrane Biology · doi:10.1007/s00232-016-9937-7 · Cited by 73
The In Silico Drug Discovery Toolbox: Applications in Lead Discovery and Optimization
Bruno, A., Costantino, G., Sartori, L., & Radi, M. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666171107101035 · Cited by 78
DNA-encoded libraries – an efficient small molecule discovery technology for the biomedical sciences
Kunig, V. B. K., Potowski, M., Gohla, A., & Brunschweiger, A. (2018) · Biological Chemistry · doi:10.1515/hsz-2018-0119 · Cited by 74
Ahmed, J., Meinel, T., Dunkel, M., Murgueitio, M. S., Adams, R. A., Blasse, C., Eckert, A. P., Preißner, S., & Preißner, R. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq910 · Cited by 79
“On the other hand, the druggable genome (6) is, independent from the kind of disease, a set of proteins that are regarded as possible drug target candidates.”
BackgroundInducing protein-protein interactions with molecular glues
Che, Y., Gilbert, A. M., Shanmugasundaram, V., & Noe, M. C. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.04.046 · Cited by 70
Uncovering genetic mechanisms of hypertension through multi-omic analysis of the kidney
Eales, J., Jiang, X., Xu, X., Saluja, S., Akbarov, A., Cano-Gamez, E., McNulty, M. T., Finan, C., Guo, H., Wystrychowski, W., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00835-w · Cited by 76
From pharmacogenetics to pharmaco-omics: Milestones and future directions
Auwerx, C., Sadler, M. C., Reymond, A., & Kutalik, Z. (2022) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2022.100100 · Cited by 90
“59 Besides providing a blueprint to map genes and variants associated with drug responses, access to the reference genome catalyzed waves of technological progress in genomics (Box 3).”
BackgroundCurrent status and trends in small nucleic acid drug development: Leading the future
Miao, Y., Fu, C. S., Yu, Z., Yu, L., Tang, Y., & Wei, M. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.05.008 · Cited by 74
Chan, A., Haley, R. M., Najar, M. A., Gonzalez-Martinez, D., Bugaj, L. J., Burslem, G. M., Mitchell, M. J., & Tsourkas, A. (2024) · Nature Communications · doi:10.1038/s41467-024-50235-x · Cited by 82
Target identification and validation in drug discovery: the role of proteomics
Kopec, K. K., Bozyczko‐Coyne, D., & Williams, M. J. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.01.004 · Cited by 83
Identification of Survival Genes in Human Glioblastoma Cells by Small Interfering RNA Screening
Thaker, N. G., Zhang, F., McDonald, P. R., Shun, T. Y., Lewen, M. D., Pollack, I. F., & Lazo, J. S. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.058024 · Cited by 73
“…which comprises siRNAs targeting gene products that are potential drug targets or are disease-modifying, such as ion channels, transporters, receptors, and protein kinases, to facilitate the target identification process (Hopkins and Groom, 2002; Russ and Lampel, 2005; Overington et al., 2006).”
BackgroundMethodTargeting invadopodia to block breast cancer metastasis
Eckert, M. A., & Yang, J. (2011) · Oncotarget · doi:10.18632/oncotarget.301 · Cited by 80
“Directly inhibiting the transcription factors that drive EMT is currently infeasible, as targeting large binding interfaces is not amenable to small-molecule inhibition[9, 10].”
BackgroundOpen Access High Throughput Drug Discovery in the Public Domain: A Mount Everest in the Making
Roy, A., McDonald, P. R., Sittampalam, S., & Chaguturu, R. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110792927757 · Cited by 86
“However, there are 4500 disease modifying genes in the human genome which include ~3000 druggable (by small molecules) genes along with another 10,000 genes that are addressable by protein therapeutics [3].”
BackgroundEhrt, C., Brinkjost, T., & Koch, O. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006483 · Cited by 68
“Following the introduction of the principle of binding site druggability[74], i.”
BackgroundMorel, N. M., Holland, J. M., van der Greef, J., Marple, E. W., Clish, C., Loscalzo, J., & Naylor, S. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.5.651 · Cited by 71
PRSS3/Mesotrypsin Is a Therapeutic Target for Metastatic Prostate Cancer
Hockla, A., Miller, E. E., Salameh, M. A., Copland, J. A., Radisky, D. C., & Radisky, E. S. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0314 · Cited by 74
Takeda, H., Ogasawara, T., Ozawa, T., Muraguchi, A., Jih, P.-J., Morishita, R., Uchigashima, M., Watanabe, M., Fujimoto, T., Iwasaki, T., et al. (2015) · Scientific Reports · doi:10.1038/srep11333 · Cited by 71
A Prediction Model for Membrane Proteins Using Moments Based Features
Butt, A. H., Khan, S. A., Jamil, H., Rasool, N., & Khan, Y. D. (2016) · BioMed Research International · doi:10.1155/2016/8370132 · Cited by 71
Defining Balanced Conditions for Inhibitor Screening Assays That Target Bisubstrate Enzymes
Yang, J., Copeland, R. A., & Lai, Z. (2009) · SLAS DISCOVERY · doi:10.1177/1087057108328763 · Cited by 73
“The Km for A and B at any fixed concentration of the other substrate can be derived from equation (1) (detailed derivation can be found in the appendix):”
BackgroundOpportunities and challenges of protein-based targeted protein degradation
Shen, F., & Dassama, L. M. K. (2023) · Chemical Science · doi:10.1039/d3sc02361c · Cited by 74
Estimation of Membrane Proteins in the Human Proteome
Ahram, M. A., Litou, Z. I., Fang, R., & Al-Tawallbeh, G. (2006) · In Silico Biology · doi:10.3233/isb-00251 · Cited by 89
“A significance of these proteins is that they constitute more than 45% of current drug targets [Drews, 2000], with 25–30% of drugs targeting G-protein coupled receptors [Hopkins and Groom, 2002].”
BackgroundMitotic drivers—inhibitors of the Aurora B Kinase
Keen, N., & Taylor, S. S. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9184-9 · Cited by 70
“not every protein lends itself to therapeutic intervention; rather, only a subset of proteins are amenable to drug discovery, leading to the concept of “the druggable genome” [22].”
BackgroundChasse, S., Flanary, P. L., Parnell, S. C., Hao, N., Cha, J. Y., Siderovski, D. P., & Dohlman, H. G. (2006) · Eukaryotic Cell · doi:10.1128/ec.5.2.330-346.2006 · Cited by 80
“Approximately one-third of all drugs act by binding directly to receptors of this class (64).”
BackgroundBosutinib Therapy Ameliorates Lung Inflammation and Fibrosis in Experimental Silicosis
Carneiro, P. J., Clevelario, A. L., Padilha, G. A., Silva, J. D., Kitoko, J. Z., Olsen, P. C., Capelozzi, V. L., Rocco, P. R. M., & Cruz, F. F. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00159 · Cited by 74
“…and Brummendorf, 2012), it is not surprising that the Src signaling pathway has been successfully targeted by multiple drug-discovery programs (Hopkins and Groom, 2002; Overington et al., 2006) and has been regarded as a promising new therapeutic approach for lung diseases (Richeldi et al.,…”
BackgroundCostales, M. G., Hoch, D. G., Abegg, D., Childs‐Disney, J. L., Velagapudi, S. P., Adibekian, A., & Disney, M. D. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b10558 · Cited by 70
Eukaryotic membrane protein overproduction in Lactococcus lactis
Kunji, E. R. S., Chan, K. W., Slotboom, D.-J., Floyd, S., O’Connor, R., & Monné, M. (2005) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2005.08.006 · Cited by 70
“This central role makes them a good target for drug treatment and G-protein-coupled receptors (GPCRs), ion channels and neurotransmitter transporters currently constitute more than 40% of all established drug targets [1].”
BackgroundMüller, P., Léna, G., Boilard, É., Bezzine, S., Lambeau, G. J., Guichard, G., & Rognan, D. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0606589 · Cited by 70
Small Molecules, Big Players: the National Cancer Institute's Initiative for Chemical Genetics
Tolliday, N., Clemons, P. A., Ferraiolo, P., Koehler, A. N., Lewis, T. A., Li, X., Schreiber, S. L., Gerhard, D. S., & Eliasof, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2552 · Cited by 69
“ability of small molecules to serve as drugs by focusing on a relatively small number of biological targets, a subset of the socalled ‘‘druggable genome’’ (6).”
BackgroundRecent Update on siRNA Therapeutics
Ebenezer, O., Oyebamiji, A. K., Olanlokun, J. O., Tuszyński, J. A., & Wong, G. K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083456 · Cited by 81
“This contrasts with small molecules, where only about 15% of the genes can be targeted [1–3].”
Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication
Perwitasari, O., Yan, X., O’Donnell, J., Johnson, S. K., & Tripp, R. A. (2015) · Assay and Drug Development Technologies · doi:10.1089/adt.2015.0003.drrr · Cited by 74
“nificant and practicable therapeutic disease intervention strategy.(28,29) Kinase targeting has been extensively explored for”
Background
Metadata
- Authors
- Hopkins, A. L., & Groom, C. R.
- Affiliations
- Pfizer (United Kingdom) (GB)
- Corresponding author
- Groom, Colin R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-09
- Volume
- 1
- Issue
- 9
- Pages
- 727-730
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2074370114
- Cited by
- 3,305
- References
- 16
- Citations by year
- 2026: 91 · 2025: 113 · 2024: 131 · 2023: 116 · 2022: 155 · 2021: 150 · 2020: 144 · 2019: 147 · 2018: 136 · 2017: 132 · 2016: 144 · 2015: 182 · 2014: 162 · 2013: 161 · 2012: 212
- FWCI
- 70.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Science, Research, and Medicine
- Keywords
- druggable genome, therapeutic target, molecular targets, target identification
- MeSH terms
- Biological Availability, Chemistry, Pharmaceutical, Humans, Molecular Biology, Pharmacokinetics, Genome, Human
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.